Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376540 | 0.94 | OPRD1 (0.61) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL29509617 | 0.91 | OPRD1 (0.58) | OPRD1OPRM1 | |
| SCHEMBL5611736 | 0.91 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL5058350 | 0.91 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL29462069 | 0.89 | OPRD1 (0.65) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL28184395 | 0.88 | OPRD1 (0.52) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL29706375 | 0.88 | OPRD1 (0.52) | OPRD1OPRM1 | |
| SCHEMBL30832772 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1 | |
| SCHEMBL30832767 | 0.83 | OPRD1 (0.57) | OPRD1OPRM1 | |
| SCHEMBL31325181 | 0.81 | OPRD1 (0.71) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250647-A1 | STABLE CELL CLONES HARBORING REPLICATING SARS-COV-2 RNA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4561608-A1 | TREATMENT FOR ACUTE ORGAN INJURY USING CD39, RECOMBINANT CD39 | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-3475442-B1 | 12(S)-HYDROXYEICOSATRIENOIC ACID COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | UNIV MICHIGAN REGENTS (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240294670-A1 | ANTIBODIES TO CHITINASE 3-LIKE-1 AND METHODS OF USE THEREFOR | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-05 | — | — | US | disclosed |
| CN-111788300-B | Cell aggregation inhibitor | 株式会社钟化 | 2024-08-13 | — | — | CN | disclosed |
| US-20240102107-A1 | METHODS AND COMPOSITIONS RELATED TO T-CELL ACTIVITY | THE UNIVERSITY OF CHICAGO (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024023745-A1 | TREATMENT FOR ACUTE ORGAN INJURY USING CD39, RECOMBINANT CD39 | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11802316-B2 | Methods and compositions related to T-cell activity | THE UNIVERSITY OF CHICAGO (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3054936-B1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023103789-A1 | ANTIBODY SPECIFICALLY RECOGNIZING MASP2 AND USE THEREOF | 舒泰神（北京）生物制药股份有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230159620-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR VASCULAR DISEASES AND THROMBOSIS | WASHINGTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230129799-A1 | Methods and Compositions for Nucleic Acid Detection | ROCHE MOLECULAR SYSTEMS INC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4163387-A1 | METHODS AND COMPOSITIONS RELATED TO T-CELL ACTIVITY | The University of Chicago (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916347-A | Antibodies to chitinase 3-like 1 and methods of use thereof | 德克萨斯大学系统董事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4139004-A2 | ANTIBODIES TO CHITINASE 3-LIKE-1 AND METHODS OF USE THEREFOR | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220347113-A1 | PEPTIDES AND METHODS OF TREATING SEPSIS, ATHEROSCLEROSIS, THROMBOSIS, STROKE, HEART ATTACK AND INFLAMMATION | UNIV ILLINOIS (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3404116-B1 | METHODS AND COMPOSITIONS RELATED TO T-CELL ACTIVITY | UNIV CHICAGO (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-4055032-A1 | PEPTIDES AND METHODS OF TREATING SEPSIS, ATHEROSCLEROSIS, THROMBOSIS, STROKE, HEART ATTACK AND INFLAMMATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-14 | — | — | EP | disclosed |
| US-11421268-B2 | Methods and compositions for nucleic acid detection | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | OPRD1 819/4885OPRM1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.